Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TransMedics GroupTMDX -0.69%69 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus rates TMDX with a GF Score™ of 69/100 and a GF Value™ of $169.83 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 323 Medical Devices & Instruments companies, TransMedics Group ranks worse than 309597.21% on this metric.
TransMedics Group's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for TransMedics Group's 5-Year Yield-on-Cost % or its related term are showing as below:
TMDX's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.42 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TransMedics Group (NAS:TMDX) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
TransMedics Group 5-Year Yield-on-Cost % Related Terms
TMDX vs AXGN, BFLY, ESTA: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, TransMedics Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where TransMedics Group's 5-Year Yield-on-Cost % falls into.
TransMedics Group 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
TransMedics Group (TMDX) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TransMedics Group and its competitors. According to the industry distribution chart, TransMedics Group ranks #999999 out of 323 companies in the Medical Devices & Instruments industry.
Is TransMedics Group's 5-Year Yield-on-Cost % too high?
TransMedics Group's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, TransMedics Group ranks #999999 out of 323 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TransMedics Group has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's 5-Year Yield-on-Cost % compare to AXGN and BFLY?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #999999 out of 323 companies for 5-Year Yield-on-Cost %. This places TransMedics Group in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.42, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on TransMedics Group and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $169.83, compared to a current price of $73.47 — trading 56.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For TransMedics Group (TMDX), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (TMDX) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of $73.47 is trading 56.7% below its estimated GF Value™ of $169.83.
GuruFocus considers TransMedics Group to be Possible Value Trap.
Key valuation signals for TMDX:
5-Year Yield-on-Cost %: 0.00
GF Value™: $169.83 vs. price of $73.47 (56.7% below fair value)
No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score
Get the complete analysis for TMDX
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMDX has been successfully added to your 
